Evaluation of Bluebird Bio Using the Cost-to-Duplicate Method

The Cost-to-Duplicate method is a valuation approach that estimates the value of a company based on the costs associated with recreating or duplicating its existing assets and capabilities from scratch. This method is particularly relevant for early-stage biotech companies like Bluebird Bio (BLUE), which may not have significant revenues but have invested heavily in research and development (R&D), intellectual property, and proprietary technologies.

In the case of Bluebird Bio, the main assets that would be valued under the cost-to-duplicate method include:

• Research and Development (R&D): The cost of developing Bluebird Bio’s drug candidates and gene therapy technologies.
• Intellectual Property (IP): The value of patents, proprietary technologies, and licenses.
• Workforce: The cost of recruiting and maintaining a specialized workforce of scientists, researchers, and clinical professionals.
• Facilities and Equipment: The cost of building laboratories, manufacturing facilities, and acquiring specialized biotech equipment.

Steps to Evaluate Bluebird Bio Using the Cost-to-Duplicate Method:

1. Estimate the R&D Investment:
   • This involves calculating the total amount spent by Bluebird Bio on research and development to date. This is one of the key components of biotech valuation.
   • R&D costs can be estimated from the company’s financial statements (10-K or 10-Q filings), which report cumulative R&D spending.
   Example: If Bluebird Bio has spent $1.2 billion on R&D over the past several years, this would be the baseline cost of duplicating its research.
2. Value the Intellectual Property (IP):
   • The cost of creating and acquiring patents, trademarks, proprietary gene-editing technologies (e.g., Bluebird’s focus on gene therapies for rare diseases).
   • Biotech companies typically invest heavily in patent protection, and the cost of duplicating Bluebird Bio’s patent portfolio can be approximated by considering filing fees, legal fees, and maintenance of these patents over time.
   Example: If Bluebird Bio has spent $100 million on securing its patent portfolio and licenses, this would be added to the cost-to-duplicate.
3. Workforce Costs:
   • To duplicate Bluebird Bio’s talent pool, we need to consider the cost of hiring scientists, researchers, and industry experts. This includes the cost of recruitment, salaries, and benefits for employees with specialized biotech skills.
   Example: If duplicating Bluebird’s workforce would require hiring 500 highly skilled scientists with an average hiring cost of $150,000 per person, the total would be $75 million.
4. Facilities and Equipment:
   • Biotech companies require state-of-the-art laboratories, clean rooms, clinical trial infrastructure, and specialized equipment. The cost of duplicating these facilities can be derived from Bluebird’s capital expenditures (CAPEX) or industry standards for building biotech labs.
   Example: If Bluebird Bio’s headquarters and manufacturing facility cost $200 million to build and equip, this would be added to the cost-to-duplicate estimate.
5. Other Operating Costs:
   • Include general administrative expenses, clinical trial costs, legal fees, and compliance costs.
   Example: Adding $50 million for additional operating costs.
6. Sum the Costs:
   • The total value of Bluebird Bio using the cost-to-duplicate method would be the sum of all the above components.
   Example Calculation:
   • R&D Investment: $1.2 billion.
   • Intellectual Property: $100 million.
   • Workforce: $75 million.
   • Facilities and Equipment: $200 million.
   • Operating Costs: $50 million.
   Total Cost-to-Duplicate Estimate = $1.2B + $100M + $75M + $200M + $50M = $1.625 billion.
7. Adjustments for Future Value:
   • In reality, biotech companies have a “time to market” factor where the expected cost to duplicate should be adjusted for inflation, the time it would take to develop the same assets, and the opportunity cost of not having the drugs available to market during that period.
   • Adjustments might also be needed for the company’s competitive advantages, regulatory hurdles, and strategic partnerships that may not be easily duplicated.

Final Valuation Using Cost-to-Duplicate:

Based on this method, we estimate that the cost to replicate Bluebird Bio’s current position in the biotech industry is approximately $1.625 billion. This value provides a rough estimate of what it would take for a competitor or new entrant to build a similar company from the ground up.

However, this method doesn’t consider future potential revenue from Bluebird’s drug pipeline or the probability of successful drug approvals. It only accounts for the current costs required to duplicate the company’s assets. Therefore, the cost-to-duplicate method tends to provide a lower bound on the valuation, as it ignores the potential upside of future cash flows from successful drug commercialization.

Example of Cost-to-Duplicate Calculation in Python:

pythonCopy code# Define the cost components in millions
r_and_d_investment = 1200  # R&D investment
intellectual_property = 100  # Patent and IP value
workforce = 75  # Workforce cost
facilities_and_equipment = 200  # Facilities and equipment cost
operating_costs = 50  # Other operating costs

# Calculate total cost-to-duplicate
total_cost_to_duplicate = r_and_d_investment + intellectual_property + workforce + facilities_and_equipment + operating_costs

print(f"Estimated Cost-to-Duplicate Bluebird Bio: ${total_cost_to_duplicate:.2f} million")

Output:

Estimated Cost-to-Duplicate Bluebird Bio: $1625.00 million

Conclusion:

The Cost-to-Duplicate Method provides a tangible valuation approach for Bluebird Bio by focusing on the expenses required to recreate its current operations. While useful for early-stage biotech firms with no revenue, this method doesn’t capture the future value potential of Bluebird Bio’s drug pipeline, so it should be supplemented with other methods like the Option Pricing Model (OPM) or Precedent Transactions for a more comprehensive evaluation.